Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Anidulafungin Clear all
Completed Phase 3 Interventional

Anidulafungin Versus Fluconazole in the Treatment of Candidemia

NCT00058682
View directory record Official record
Conditions
Candida, Candidiasis
Interventions
Anidulafungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 3:00 PM EDT
Not yet recruiting No phase listed Observational

A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

NCT06907992
View directory record Official record
Conditions
Candidemia
Interventions
Antifungal treatment
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 2, 2026, 3:00 PM EDT
Completed No phase listed Observational

Antimicrobial PK in Infants With Suspected or Confirmed Infection

NCT00491426
View directory record Official record
Conditions
Infection
Interventions
Ampicillin, Metronidazole, Piperacillin/Tazobactam, Acyclovir, Amphotericin B, Ambisome, Anidulafungin, Caspofungin
Drug
Lead sponsor
Duke University
Other
Eligibility
Up to 120 Days
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2012 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations

NCT01307930
View directory record Official record
Conditions
Obesity, Mycoses
Interventions
Anidulafungin
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

NCT00940017
View directory record Official record
Conditions
Aspergillosis, Candidemia
Interventions
anidulafungin and voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2010 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 4 Interventional Results available

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

NCT00841971
View directory record Official record
Conditions
Mycoses, Fungemia, Central Nervous System Fungal Infections, Lung Diseases, Fungal
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

NCT00037219
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 2, 2026, 3:00 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Echinocandin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17

NCT00056381
View directory record Official record
Conditions
Neutropenia
Interventions
Anidulafungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 1 Interventional Results available

Anidulafungin PK in Infants and Toddlers

NCT00734500
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
Anidulafungin
Drug
Lead sponsor
Michael Cohen-Wolkowiez
Other
Eligibility
48 Hours to 24 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)

NCT00041704
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2008 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

NCT00056368
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 3 Interventional Results available

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

NCT00761267
View directory record Official record
Conditions
Candidemia
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Month to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
24
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 2, 2026, 3:00 PM EDT
Terminated Phase 4 Interventional Results available

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

NCT00620074
View directory record Official record
Conditions
Aspergillosis
Interventions
voriconazole, anidulafungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • Detroit, Michigan • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 2, 2026, 3:00 PM EDT
Completed No phase listed Observational

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

NCT01686607
View directory record Official record
Conditions
Systemic Fungal Infections
Interventions
Parenteral micafungin application, Other parenteral antifungal drugs
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
Not listed
Enrollment
40,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 1Phase 2 Interventional

Anidulafungin in Treating Immunocompromised Children With Neutropenia

NCT00068471
View directory record Official record
Conditions
Infection, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anidulafungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 2Phase 3 Interventional

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

NCT00037206
View directory record Official record
Conditions
Aspergillosis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 3 Interventional Results available

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

NCT00531479
View directory record Official record
Conditions
Aspergillosis
Interventions
voriconazole, anidulafungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Not applicable Interventional Results available

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

NCT00672841
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Preemptive Therapy with Anidulafungin, Empiric antifungal therapy based on physician discretion.
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Sep 2, 2026, 3:00 PM EDT
Completed Phase 4 Interventional Results available

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

NCT00496197
View directory record Official record
Conditions
Candidiasis
Interventions
Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Sep 2, 2026, 3:00 PM EDT
Terminated Phase 3 Interventional Results available

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

NCT00805740
View directory record Official record
Conditions
Candidiasis, Fungemia
Interventions
Active anidulafungin, Active Caspofungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Newark, Delaware • Wilmington, Delaware • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Sep 2, 2026, 3:00 PM EDT